Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Suicide Warning on Atomoxetine

The manufacturers of Atomoxetine (Strattera) have updated the Summary of Product Characteristics to include a warning about suicide related behaviour.

Suicide related behaviour is defined as suicidal ideation or a suicide attempt. In double blind clinical trials suicide related behaviour occurred in about 0.5% of patients taking Atomoxetine, this behaviour was absent in the placebo arms of the studies.

Action: Patients (and their parents or guardians) should be made aware of this new information. Any behavioural changes including depression, suicidal ideation or suicide attempts should prompt a rapid referral for re-assessment and a change of treatment if necessary.

Share 'Suicide Warning on Atomoxetine' on Email Share 'Suicide Warning on Atomoxetine' on Delicious Share 'Suicide Warning on Atomoxetine' on Digg Share 'Suicide Warning on Atomoxetine' on Facebook Share 'Suicide Warning on Atomoxetine' on Google+ Share 'Suicide Warning on Atomoxetine' on reddit Share 'Suicide Warning on Atomoxetine' on StumbleUpon Share 'Suicide Warning on Atomoxetine' on Twitter

atomic-wealth

No Comments to “Suicide Warning on Atomoxetine”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,621 spam comments.

atomic-wealth
fond-illness
summer